Current Ongoing Clinical Research Home Research & Academics Research Facilities Current Ongoing Clinical Research Sr. No.Research Protocol TitleAim of the studyPrincipal Investigator1Neuro- Injury Markers after Return of Spontaneous Circulation (ROSC) in the Setting of Cardiac Arrest (CA)To analyse the blood concentrations and post-resuscitation kinetics of neuron specific enolase [NSE] and ubiquitin carboxy-terminal hydrolase-L1 (UCH-L-1) in predicting the neurological outcome in patients with cardiac arrest (CA) and return of spontaneous circulation (ROSC), in combination with electrophysiological, neuroimaging and clinical neurological examinationDr. Darshana Rathod2Adrenomedullin: Marker for Organ failure and Mortality in Sepsis and Septic ShockTo assess in septic patients (in ICU), the relation between circulating adrenomedullin and sepsis, septic shock, the need for organ support and mortality using an assay of bio-ADM and MR-ProADM and compare the same with non-septic IC patients.Dr. Darshana Rathod3Molecular characterization of high risk Human papillomavirus (HPV) in P16 - IHC positive and negative Head and Neck Squamous Cell Carcinoma (HNSCC) casesHPV positive HNSCC is a distinct subgroup characterized by specific biological and clinical profiles as compared to HPV negative HNSCC. Study aims at identifying the active HPV infection i. e. HPV E6/E7 expression and correlating with HPV genotype and p16 IHC status and grouping oral cavity cancer and OPSCC cases accordinglyDr. Vijay Haribhakti4The cardiovascular safety of cagrilintide 2.4 mg s.c. in combination with semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) once-weekly in participants with obesity and established cardiovascular disease. REDEFINE3To assess the cardiovascular (CV) safety of CagriSema 2.4 mg/2.4 mg versus placebo, both administered subcutaneously (s.c.) once-weekly and both added to standard of care in individuals with obesity and established cardiovascular disease (CVD).Dr. Muffazal Lakdawala5An Open-Label, Single-Arm, Prospective, Multicenter, Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Human Normal Immunoglobulin for Intravenous Use in Adult and Paediatric Subjects with Primary Immunodeficiency Syndrome.This study is conducted to evaluate the efficacy, safety, and pharmacokinetics of IVIG (Human) 5% in adult and pediatric patients with PID in Indian population. The data from this clinical study are planned to be submitted to health authorities of countries and regions across the world that require such data for authorization of IVIG.Dr. Shweta Bansal6Impact assessment of Carba-R screening protocol on patient outcome for CRE ratesTo compare the impact of Xpert Carba-R screening on the incidence of CRE infections/ colonization at four locations in hospital ICU's and high care ward. (Pre and post intervention).Dr. Rahul Pandit7A Phase III, Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared with Fulvestrant, Both Combined with A CDK4/6 Inhibitor, In Patients with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer with Resistance to Prior Adjuvant Endocrine Therapy pionERA-C044657To demonstrate a statistically significant and clinically meaningful progression free survival (PFS) benefit of Giredestrant compared with Fulvestrant, each combined with the investigator's choice of cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) between Palbociclib, Abemaciclib and Ribociclib, as first-line (1L) treatment of Estrogen Receptor-Positive (ER+), HER2-negative (HER2-) Advanced Breast Cancer (aBC) resistant to adjuvant endocrine therapy (ET), a patient group considered to have a particularly high unmet need.Dr. Sewanti Limaye8To Monitor the efficacy and side effects of GLP1 Anlagos in patients visiting Endocrine OPD in Sir HN Foundation Hospital.a. To Monitor side effects of GLP1 Analogs. b. To Monitor weight loss among patients on GLP1 Analogs.Dr. David Chandy9Effect of Non-surgical periodontal therapy (NSPT) on HbA1C levels in Diabetes Mellitus patients: A Randomized Controlled Study.The aim of this study is to assess the effect of Non-Surgical Periodontal Treatment on HbA1c in Diabetes Mellitus patients and chronic periodontitis for 2 years. (Evaluate, investigate and compare in gingival indices with and without treatment)Dr. Gauri Merchant10A multi-centric, open-label, comparative, randomized, phase 3 trial to evaluate the efficacy and safety of Aviptadil as an add-on treatment to the Standard of Care in acute respiratory distress syndrome.1. To evaluate the efficacy of Aviptadil as an add-on treatment to the Standard of Care in patients with Acute Respiratory Distress Syndrome (ARDS).2. To evaluate the safety of Aviptadil in patients with ARDS.Dr. Rahul Pandit11Assessment of Knowledge: Reluctance and Enabling Factors Influencing HPV Vaccine Uptake Among Parents of Children eligible for HPV vaccination in Mumbai communities being served by the Outreach program of the Sir HN Reliance Foundation HospitalTo assess the knowledge of parents on HPV vaccines and enabling factors on the uptake of HPV vaccine and identify the role of awareness campaign and free of cost vaccination on the uptake. This study aims to evaluate the factors contributing to both hesitancy and acceptance of the human papillomavirus (HPV) vaccine among parents whose children are eligible for receiving the vaccine. Understanding these determinants is critical for programs to improve vaccination rates and addressing barriers that limit vaccine uptake. Key enabling factors often include parental knowledge about HPV and the vaccine, positive attitudes towards vaccination, and healthcare provider recommendations. Conversely, reluctance may stem from concerns about vaccine safety, lack of awareness, cultural beliefs, and logistical challenges such as access to healthcare services. By identifying and analysing these factors in a typical Mumbai population, this assessment seeks to inform targeted interventions that can enhance parental acceptance and increase HPV vaccination coverage among eligible children.Dr. Swati Jha12A Phase 3, Randomized, Double-blind, Multicenter Study of MK-1084 in Combination with Pembrolizumab Compared with Pembrolizumab Plus Placebo as Firstline Treatment of Participants with KRAS G12C-Mutant, Metastatic NSCLC with PD-L1 TPS ≥50% (MK1084-004)To compare MK-1084 plus pembrolizumab with placebo plus pembrolizumab with respect to PFS assessed according to RECIST 1.1 by BICR Hypothesis (H1): Combination of MK-1084 and pembrolizumab is superior to placebo plus pembrolizumab with respect to PFS per RECIST 1.1 by BICR (Blinded Independent Central Review)Dr. Sewanti Limaye13A Prospective Observational study to assess the feasibility and safety of administering weekly albumin infusions at home and its impact on Quality of LifeTo assess the feasibility and safety of administering weekly albumin infusions at home and its impact on Quality of life.Dr. Akash Shukla14Prevalence of Frailty and its association with Muscle specific indicators in eldersThe aim of the present study is to estimate the identification of frailty and analyse its association with 3-methyl histidine (3-MH), a potential indicator to display an elevated muscle protein turnover which in-turn is linked to frailty, in elderly population.Dr. Preeti Chhabaria15“A Phase 4, non-randomized, multicenter, open-label, single-arm study to evaluate the safety and efficacy of Saroglitazer 4 mg in patients with non-alcoholic fatty liver disease (NAFLD) with comorbidities (either obesity, type 2 diabetes mellitus, dyslipidemia or metabolic syndrome)”.to evaluate the safety and efficacy of Saroglitazar 4 mg once daily in patients with NAFLD with comorbidities (either obesity, type 2 diabetes mellitus, dyslipidemia or metabolic syndrome).Dr. Amit Gupte16The Burden of Penicillin and other Antibiotic Allergy Labels and Antimicrobial Resistance in Low and Middle-Income Countries (PALAR study India)To undertake a real time prospective observational study to gain insights into the burden of drug allergy labels (DALs), AALs and AMR in India.Dr. Sunita Chhapola Shukla